Literature DB >> 35116040

Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges.

Jiaxuan Chen1, Shuzhen Liao1, Huimin Zhou2, Lawei Yang1, Fengbiao Guo1, Shuxian Chen1, Aifen Li1, Quanren Pan1, Chen Yang1, Hua-Feng Liu1, Qingjun Pan1.   

Abstract

Animal models have played a crucial role in the understanding of the mechanisms and treatments of human diseases; however, owing to the large differences in genetic background and disease-specific characteristics, animal models cannot fully simulate the occurrence and progression of human diseases. Recently, humanized immune system mice, based on immunodeficient mice, have been developed that allow for the partial reconstruction of the human immune system and mimic the human in vivo microenvironment. Systemic lupus erythematosus (SLE) is a complex disease characterized by the loss of tolerance to autoantigens, overproduction of autoantibodies, and inflammation in multiple organ systems. The detailed immunological events that trigger the onset of clinical manifestations in patients with SLE are still not well known. Two methods have been adopted for the development of humanized SLE mice. They include transferring peripheral blood mononuclear cells from patients with SLE to immunodeficient mice or transferring human hematopoietic stem cells to immunodeficient mice followed by intraperitoneal injection with pristane to induce lupus. However, there are still several challenges to be overcome, such as how to improve the efficiency of reconstruction of the human B cell immune response, how to extend the lifespan and improve the survival rate of mice to extend the observation period, and how to improve the development of standardized commercialized models and use them. In summary, there are opportunities and challenges for the development of humanized mouse models of SLE, which will provide novel strategies for understanding the mechanisms and treatments of SLE.
Copyright © 2022 Chen, Liao, Zhou, Yang, Guo, Chen, Li, Pan, Yang, Liu and Pan.

Entities:  

Keywords:  autoantibodies; humanized SLE mouse; immunodeficient mouse; lupus nephritis; pro-inflammatory cytokines; systemic lupus erythematosus

Mesh:

Substances:

Year:  2022        PMID: 35116040      PMCID: PMC8804209          DOI: 10.3389/fimmu.2021.816956

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  81 in total

Review 1.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

2.  Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo.

Authors:  R Yung; S Chang; N Hemati; K Johnson; B Richardson
Journal:  Arthritis Rheum       Date:  1997-08

Review 3.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.

Authors:  Feng Yu; Mark Haas; Richard Glassock; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

4.  Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.

Authors:  Y Kalechman; U Gafter; J P Da; M Albeck; D Alarcon-Segovia; B Sredni
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

5.  Chloroquine Autophagic Inhibition Rebalances Th17/Treg-Mediated Immunity and Ameliorates Systemic Lupus Erythematosus.

Authors:  Ning An; Yanwen Chen; Chao Wang; Chen Yang; Zhi-Hong Wu; Jing Xue; Lin Ye; Shujun Wang; Hua-Feng Liu; Qingjun Pan
Journal:  Cell Physiol Biochem       Date:  2017-11-14

6.  Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression.

Authors:  Heidy Zinger; Eran Eilat; Asher Meshorer; Edna Mozes
Journal:  Int Immunol       Date:  2003-02       Impact factor: 4.823

7.  Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus.

Authors:  F Erkeller-Yüsel; F Hulstaart; I Hannet; D Isenberg; P Lydyard
Journal:  Lupus       Date:  1993-08       Impact factor: 2.911

8.  Nanoparticles Engineered as Artificial Antigen-Presenting Cells Induce Human CD4+ and CD8+ Tregs That Are Functional in Humanized Mice.

Authors:  Sophia Giang; David A Horwitz; Sean Bickerton; Antonio La Cava
Journal:  Front Immunol       Date:  2021-05-26       Impact factor: 7.561

9.  A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice.

Authors:  Merry Gunawan; Zhisheng Her; Min Liu; Sue Yee Tan; Xue Ying Chan; Wilson Wei Sheng Tan; Shubasree Dharmaraaja; Yong Fan; Chee Bing Ong; Eva Loh; Kenneth Tou En Chang; Thiam Chye Tan; Jerry Kok Yen Chan; Qingfeng Chen
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

10.  Targeted knockdown of Kv1.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus.

Authors:  Marat Khodoun; Ameet A Chimote; Farhan Z Ilyas; Heather J Duncan; Halima Moncrieffe; K Shashi Kant; Laura Conforti
Journal:  Sci Adv       Date:  2020-11-18       Impact factor: 14.136

View more
  1 in total

Review 1.  Life factors acting on systemic lupus erythematosus.

Authors:  Jiaxuan Chen; Shuzhen Liao; Wanxian Pang; Fengbiao Guo; Lawei Yang; Hua-Feng Liu; Qingjun Pan
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.